Related Experiment Video
Updated: Jun 29, 2025
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Interferon Regulatory Factor 4 (IRF4) Plays a Key Role in Osteoblast Differentiation of Postmenopausal Osteoporosis
Xuan Wu1, Cuicui Yang2, Xiangxu Chen1
1Department of Orthopedics, Zhong Da Hospital, School of Medicine, Southeast University, 210009 Nanjing, Jiangsu, China.
Background:
Postmenopausal osteoporosis (PMOP) is a prevalent disease, which features decreased bone mass, bone weakness and deteriorated bone microstructure in postmenopausal women. Although many factors have been revealed to contribute to the occurrence of PMOP, its mechanism remains undefined. This work aimed to identify significant changes in gene expression during PMOP formation and to examine the most valuable differential genes in postmenopausal osteoporosis versus the control group.
Methods:
The GSE68303 dataset that contains 12 ovariectomize (OVX) experimental and 11 sham groups was downloaded and analyzed. The results indicated that interferon regulatory factor 4 (IRF4) might be a hub gene in the development of postmenopausal osteoporosis. Western blot and immunohistochemistry were carried out to evaluate IRF4 levels in thoracic vertebra extracts from OVX and Sham mice. To assess IRF4's impact on osteogenic differentiation in postmenopausal bone marrow mesenchymal stem cells (BM-MSCs), IRF4 overexpression (OV-IRF4) and knockdown (Sh-IRF4) plasmids were constructed.
Results:
The results showed that comparing with the sham group, bone samples from the OVX group showed higher IRF4 expression. Alkaline phosphatase (ALP) staining revealed that IRF4 overexpression significantly inhibited ALP activity, while IRF4 knockdown promoted ALP activity in BM-MSCs. Simvastatin-treated OVX mice showed increased total bone volume/total tissue volume (BV/TV) and elevated Runx2 expression by immunohistochemical staining compared with the OVX group.
Conclusions:
This study demonstrated that IRF4 is associated with OVX induced osteoporosis, it can regulate bone stability by inhibiting the osteogenic differentiation BM-MSCs. This study may help enhance our understanding of the molecular mechanism of PMOP formation, providing new insights into estrogen defiance induced osteoporosis.
Insights
Interferon regulatory factor 4 (IRF4) plays a key role in postmenopausal osteoporosis by inhibiting bone formation. Targeting IRF4 may offer new therapeutic strategies for this common bone disease.
Area of Science:
- Bone Biology and Disease
- Molecular Mechanisms of Osteoporosis
- Gene Expression Profiling
Background:
- Postmenopausal osteoporosis (PMOP) is a widespread condition characterized by reduced bone mass and microstructural deterioration.
- The precise molecular mechanisms underlying PMOP remain incompletely understood.
- Identifying key genes involved in PMOP pathogenesis is crucial for developing effective treatments.
Purpose of the Study:
- To identify significant gene expression changes associated with PMOP.
- To investigate the role of interferon regulatory factor 4 (IRF4) as a potential hub gene in PMOP.
- To explore the impact of IRF4 on osteogenic differentiation in bone marrow mesenchymal stem cells (BM-MSCs).
Main Methods:
- Analysis of the GSE68303 dataset comparing ovariectomized (OVX) and sham mice.
- Western blot and immunohistochemistry to assess IRF4 levels in mouse bone tissue.
- In vitro experiments using IRF4 overexpression (OV-IRF4) and knockdown (Sh-IRF4) in BM-MSCs.
Main Results:
- OVX mice exhibited significantly higher IRF4 expression compared to sham controls.
- IRF4 overexpression inhibited alkaline phosphatase (ALP) activity, while IRF4 knockdown promoted it in BM-MSCs.
- Simvastatin treatment in OVX mice increased bone volume and Runx2 expression.
Conclusions:
- IRF4 is implicated in OVX-induced osteoporosis and regulates bone stability by inhibiting osteogenic differentiation of BM-MSCs.
- These findings enhance the understanding of PMOP molecular mechanisms.
- The study provides novel insights into estrogen deficiency-induced osteoporosis.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...